Clinical Evidence Library
Clinical evidence from guidelines, trials, biomedi…
Fast facts on ClinicalTrials.gov results quality. Build five cards around the strongest quantitative and interpretive findings: 79,413 registry records, 2,178 posted results records, 20 percent with more than two primary outcomes, 61 percent lacking specificity in planned analysis metric, and the self reported nature of the data. Frame the deck as historical quality signals rather than current registry performance.
This is a retrospective look at registry quality signals in ClinicalTrials.gov, not a report of current performance. The registry-record analysis examined 79,413 ClinicalTrials.gov records. In the planned-analysis sample, 61% of first primary outcome entries were too vague to identify a measurement ...
ViewCan AI safely accelerate evidence synthesis?. Build a knowledge-check quiz around what AI tools can and cannot reliably do in systematic review workflows and evidence-disagreement detection. Include items on screening, data extraction, risk-of-bias assessment, human validation, selective reporting, and fine-grained population extraction failures.
Q1. According to the systematic review, which task did AI methods appear to be used for most often in evidence synthesis workflows? - Study screening - Data extraction - Risk-of-bias assessment - Selective reporting detection Answer: Study screening[[cite:1]] Q2. What did the review say about the re...
ViewWhy GLP-1 discontinuation matters for evidence interpretation. Produce a sub two minute narrated explanation that separates trial efficacy from persistence and tolerability in practice. Close with the evidence-review question of whether outcomes are durable when treatment is stopped or doses differ from trial protocols.
When comparing semaglutide and tirzepatide for weight loss, it matters whether we are looking at trial efficacy or real-world use. Trials test ideal dosing and steady treatment, but in practice many patients stop early, stay on treatment inconsistently, or use lower doses than the trials studied. Th...
ViewPCOS guidelines: what changed from 2018 to 2023?. Walk readers through the shift from 2018 to 2023 as refinement rather than reversal. Emphasize streamlined diagnosis, AMH as an adult-only ultrasound alternative, broader cardiometabolic and psychological risk recognition, and the continued low-to-moderate evidence base.
Did the 2023 PCOS guideline change everything? Not really. It builds on 2018 with the same evidence-based core, just a cleaner diagnostic pathway and broader recognition of what PCOS affects[[cite:1]]. The biggest diagnostic shift is refinement: adults still use the established framework, but 2023 s...
ViewLong-acting growth hormone in children: what remains uncertain?. Synthesize the consensus and related evidence around which pediatric patients may benefit from long-acting growth hormone and why adherence matters. Separate practical considerations from evidence gaps, especially long-term efficacy, safety, real-world follow-up, and concerns about weekly exposure profiles.
Long-acting growth hormone in children: current consensus and where it fits The current consensus is that long-acting growth hormone (LAGH) is a meaningful once-weekly alternative to daily recombinant human growth hormone for children with growth hormone deficiency, with phase 3 trials showing non-i...
ViewWhen do systematic reviews miss harms?. Narrate why adverse events may be underdetected when reviews rely on randomized trials alone. Explain the need to combine trial data with post-marketing surveillance, spontaneous reports, epidemiology, and unpublished evidence while pre-specifying harms and follow-up.
When systematic reviews of semaglutide or tirzepatide rely on randomized trials alone, they can miss important harms. The trials may include too few people to detect rare adverse events, and they may end before delayed harms appear. Published trial reports can also leave out a lot of adverse event i...
View- 1(current)